For a 55-year-old male with hypogonadism who stopped testosterone and hCG due to erythrocytosis (hematocrit 53%), what is the appropriate plan for holding testosterone/hCG, timing repeat CBC and therapeutic phlebotomy, and how should I pursue insurance prior‑authorization for Wegovy (semaglutide) to treat his MASLD/MASH with F2 fibrosis and associated metabolic abnormalities?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management Plan for TRT-Induced Erythrocytosis and Wegovy Prior Authorization

Immediate Response to Patient

You should proceed with repeat labs now (after your Thursday blood donation) and wait for those results before any additional phlebotomy. The therapeutic phlebotomy order was intended as a one-time intervention to lower your hematocrit below 48% before restarting testosterone, not as a recurring every-two-weeks schedule 1. One donation is typically sufficient, though a second may be needed only if your post-donation hematocrit remains elevated above 48%.

Regarding Wegovy: I will submit a prior authorization to your insurance for Wegovy (semaglutide 2.4 mg weekly subcutaneous) specifically for your MASLD/MASH with F2 fibrosis, which is now an FDA-approved indication 2, 3. Your FibroScan showing F2 fibrosis (8.1 kPa liver stiffness) with moderate steatosis (CAP 320 dB/m), combined with metabolic risk factors (BMI 33.9, hyperlipidemia, elevated ALT 47), meets criteria for this indication 3.

Testosterone/HCG Management Algorithm

Current Status Assessment

  • Hematocrit 53% on recent testing (above the 48% threshold for TRT contraindication) 1
  • Total testosterone 526 ng/dL off therapy (mid-range, indicating some endogenous recovery)
  • One month off testosterone, two weeks off HCG

Holding Therapy Decision Tree

Continue holding both testosterone AND HCG until hematocrit normalizes below 48% 1. The Endocrine Society guideline explicitly states that clinicians should withhold testosterone therapy until hematocrit returns to normal range, then resume at a lower dose 1. Your hematocrit of 53% exceeds the 48% threshold (>50% for high-altitude residents), placing you at moderate-to-high risk for adverse outcomes 1.

Why hold HCG? HCG stimulates endogenous testosterone production and independently increases hematocrit and estradiol levels, as discussed in your visit note. Continuing HCG while trying to normalize hematocrit would be counterproductive 4.

Phlebotomy Protocol

Single therapeutic phlebotomy is appropriate, with repeat hematocrit 2-4 weeks post-donation 1, 5. The evidence supports therapeutic phlebotomy as effective for managing TRT-induced erythrocytosis, though some controversy exists about whether it increases thrombotic risk through iron depletion 6. However, the Endocrine Society guideline endorses this approach 1, and given your hematocrit of 53%, the immediate risk of thrombotic events from polycythemia outweighs theoretical concerns about phlebotomy-induced iron depletion.

Do NOT schedule recurring phlebotomy every 2 weeks. Check hematocrit 2-4 weeks after the first donation. If still >48%, consider a second donation. If <48%, proceed with TRT restart planning.

Restart Protocol (Once Hct <48%)

Restart testosterone at approximately 40% dose reduction with more frequent, smaller injections 1, 5:

  • Previous regimen: 0.25 mL twice weekly (0.5 mL total weekly)
  • Proposed restart: 0.08 mL three times weekly (0.24 mL total weekly) = 52% of previous dose
  • This approach reduces peak testosterone levels that drive erythrocytosis 4, 5

Monitor hematocrit at 3 months post-restart, then every 6-12 months 1. If hematocrit rises above 48% again, further dose reduction or switching to transdermal/nasal preparations should be considered, as injectable testosterone causes higher rates of erythrocytosis than other formulations 4.

Delay HCG reintroduction for at least 3-6 months after testosterone restart to assess hematocrit stability on testosterone alone. If testicular discomfort recurs and hematocrit remains stable <48%, reintroduce HCG at 50% of previous dose (200-250 IU three times weekly instead of 400-600 IU) 4.

Wegovy Prior Authorization Strategy

FDA-Approved Indication

Wegovy received accelerated FDA approval in August 2025 for MASH with F2-F3 fibrosis 3. Your patient qualifies based on:

  • FibroScan liver stiffness 8.1 kPa (consistent with F2 fibrosis)
  • CAP 320 dB/m (moderate steatosis)
  • Elevated ALT 47 U/L
  • Metabolic risk factors: BMI 33.9, triglycerides 213, HDL 34, family history of premature CVD

Prior Authorization Documentation

Submit PA emphasizing the MASH/fibrosis indication, NOT obesity alone 2, 3. Include:

  1. Diagnosis: Metabolic dysfunction-associated steatohepatitis (MASH) with F2 fibrosis
  2. Supporting evidence:
    • FibroScan results: liver stiffness 8.1 kPa, CAP 320 dB/m
    • ALT 47 U/L (elevated)
    • Cardiometabolic risk factors: obesity (BMI 33.9), dyslipidemia (TG 213, HDL 34), family history of premature CAD
  3. FDA indication: Wegovy approved for MASH with moderate-to-advanced fibrosis (F2-F3) per August 2025 FDA approval 3
  4. Clinical rationale: Patient meets criteria for MASH-targeted therapy per 2024 EASL-EASD-EASO guidelines 7 and 2025 AASLD guidance 3

Specify Wegovy 2.4 mg weekly subcutaneous injection pens (not Ozempic, which is indicated for diabetes) 2, 3.

If Initial Denial

Appeal with additional documentation:

  • Cite 2024 EASL-EASD-EASO guidelines stating GLP-1RAs should be used for their respective indications (obesity) and improve cardiometabolic outcomes in MASH 7
  • Reference ESSENCE trial showing 62.9% MASH resolution and 36.8% fibrosis improvement with semaglutide 2.4 mg weekly 3, 8
  • Emphasize that resmetirom (the only other FDA-approved MASH therapy) is for F2-F3 fibrosis, and your patient meets identical criteria for semaglutide 7

If insurance continues denial, explore:

  1. Employer weight-loss program benefits (as discussed)
  2. Manufacturer patient assistance program (Novo Nordisk: 1-833-WEGOVY-1) 2
  3. Cash-pay programs (typically $1,000-1,500/month)

Monitoring on Wegovy

Start at 0.25 mg weekly and titrate per FDA label 2. Given prior GI intolerance mentioned in your note, slow titration is appropriate:

  • Weeks 1-4: 0.25 mg weekly
  • Weeks 5-8: 0.5 mg weekly
  • Weeks 9-12: 1.0 mg weekly
  • Weeks 13-16: 1.7 mg weekly
  • Week 17+: 2.4 mg weekly (maintenance)

Monitor for adverse effects 2:

  • Common (counsel patient): Nausea, diarrhea, constipation, vomiting (usually mild and transient)
  • Serious (monitor clinically):
    • Acute kidney injury from dehydration (especially important given CKD Stage 2) 2
    • Gallbladder disease (patient already has gallbladder polyps under GI surveillance)
    • Pancreatitis
    • Hypoglycemia (though A1c 5.4 suggests low risk)

Hepatic monitoring: No routine liver enzyme monitoring required unless clinically indicated 3. The ESSENCE trial showed no discontinuations due to liver enzyme elevations 3.

Treatment response assessment at 72 weeks 3:

  • ALT reduction >17 U/L or ≥20% suggests MASH resolution
  • VCTE reduction ≥30% or CAP reduction ≥30% suggests improvement
  • Consider repeat FibroScan at 12-18 months

Additional Considerations

Sleep Apnea Reassessment

Pursue repeat sleep study if hematocrit remains elevated despite TRT cessation and phlebotomy 1. Sleep-disordered breathing independently causes secondary erythrocytosis and may be contributing to persistent elevation. Prior negative testing does not exclude current OSA, especially with reported snoring and BMI 33.9.

CKD Management with Wegovy

Wegovy is safe in CKD Stage 2 (eGFR 68) but requires vigilance for dehydration-induced AKI 2. Emphasize aggressive hydration, especially during GI side effects. GLP-1RAs may provide renal protection in metabolic disease 7.

Lipid Management

Continue aggressive lipid management given strong family history of premature CVD, current dyslipidemia (TG 213, HDL 34, LDL 99), and MASLD 7. Wegovy will improve lipid profile through weight loss, but consider adding statin therapy given cardiovascular risk profile and MASLD 7.

Anti-Nausea Prescription

Prescribe ondansetron 4-8 mg as needed for nausea (90-day supply for mail order as patient requested). This improves Wegovy tolerance during titration 2.

Summary Action Items

  1. Labs: Recheck CBC with hematocrit 2-4 weeks post-phlebotomy (patient getting labs tomorrow per message)
  2. Phlebotomy: No additional phlebotomy unless post-donation hematocrit remains >48%
  3. TRT/HCG: Continue holding both until hematocrit <48%, then restart testosterone at ~50% dose with more frequent injections
  4. Wegovy PA: Submit prior authorization emphasizing MASH with F2 fibrosis indication, include FibroScan results and metabolic risk factors
  5. Anti-nausea: Prescribe ondansetron 4-8 mg PRN, 90-day supply
  6. Follow-up: Schedule visit 2 weeks after lab results to review hematocrit and finalize TRT restart plan

References

1
Guideline

testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2018

Related Questions

What is the recommended management for a patient on testosterone therapy who develops erythrocytosis (hematocrit >54%) and iron deficiency?
How should polycythemia be managed in a patient receiving testosterone injections?
In a 57-year-old male who underwent a second 1800 mg BioTE testosterone pellet insertion and is taking dimethyl sulfone (DIM) 2 tablets daily, with recent labs showing hemoglobin 16.2 g/dL, hematocrit 48.6 % and SHBG 36 nmol/L, what management steps should be taken?
Should testosterone therapy be discontinued in a patient with an elevated hematocrit while using testosterone gel (Androgel) who is already seeing urology?
What is the next step for a patient on long‑term intramuscular testosterone therapy who has a routine hematocrit of 48.6%?
What are the causes of bilateral orchitis?
What are the appropriate caloric and protein targets for nutritional build‑up in a 70‑kg adult patient?
Can a maxillary sinus fungal ball (mycetoma) progress to invasive fungal sinusitis when a patient begins chemotherapy?
Is it reasonable to repeat a fasting lipid panel when the LDL (low-density lipoprotein) is 119 mg/dL, triglycerides (TG) are 83 mg/dL, HDL (high-density lipoprotein) is 57 mg/dL, and total cholesterol (TC) is 189 mg/dL?
Which laboratory tests should be ordered and monitored for a patient on warfarin therapy?
What American Society of Anesthesiologists (ASA) physical status classification applies to a 70‑kg adult needing nutritional support with no major organ failure but likely mild chronic conditions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.